Discovery of a Novel, Selective and Short-Acting Skeletal Myosin II Inhibitor
Radnai, L.; Surman, M.; Hafenbreidel, M.; Young, E. J.; Stremel, R. F.; Lin, L.; Pasetto, P.; Jin, X.; Geedy, M.; Partridge, J.-R.; Patel, A.; Conlon, M.; Sellers, J. R.; Cameron, M. D.; Rumbaugh, G.; Griffin, P.; Kamenecka, T. M.; Miller, C. A.
Show abstract
Myosin IIs, actin-based motors that utilize the chemical energy of ATP to generate force, have potential as therapeutic targets. Their heavy chains differentiate the family into muscle (skeletal [SkMII], cardiac, smooth) and nonmuscle myosin IIs. Despite therapeutic potential for muscle disorders, no SkMII-specific inhibitor has been reported and characterized. Here we present the discovery, synthesis and characterization of "skeletostatins", novel derivatives of the pan-myosin II inhibitor blebbistatin, with selectivity within the myosin IIs for SkMII. In addition, the skeletostatins bear improved potency, solubility and photostability, without cytotoxicity. Based on its optimal in vitro profile, Skeletostatin 1s in vivo tolerability, efficacy and pharmacokinetics were determined. Skeletostatin 1 was well-tolerated in mice, impaired motor performance, and had an excellent muscle to plasma ratio. Skeletostatins are useful probes for basic research and a strong starting point for drug development.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Modulation of endogenous opioid signaling by inhibitors of puromycin sensitive aminopeptidase 97%
- Development of pyrazolopyrimidine based macrocyclic kinase inhibitors targeting AAK1 96%
- Optimization of pyrazolopyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor 96%
Similar papers in this journal
- 17-Oxime ethers of oxidized ecdysteroid derivatives modulate oxidative stress in human brain endothelial cells and dose-dependently might protect or damage the blood-brain barrier 95%
- Exploring novel fluorine rich fuberidazole derivatives as hypoxic cancer inhibitors: design, synthesis, pharmacokinetics, molecular docking and DFT evaluations 95%
- A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) Technology: Development of Targeted Apoptosis Initiators for Cancer Treatment. 95%
Similar papers in this journal
- Target-driven design of a coumarinyl chalcone scaffold based novel EF2 Kinase inhibitor suppresses breast cancer growth in vivo 95%
- A hybrid in silico approach reveals novel inhibitors of multiple SARS-CoV-2 variants 94%
- Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS- S and MERS-S pseudotyped particles 94%
Similar papers in this journal
- In depth analysis of kinase cross screening data to identify CAMKK2 inhibitory scaffolds 95%
- The Meta-Position of Phe4 in Leu-enkephalin Regulates Potency, Selectivity, Functional Activity, and Signaling Bias at the Delta and Mu Opioid Receptors 95%
- Structure-Based Design of Small-Molecule Inhibitors of Human Interleukin-6 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.